14
Participants
Start Date
March 20, 2018
Primary Completion Date
November 30, 2019
Study Completion Date
February 17, 2020
Itacitinib
Itacitinib administered orally once daily at the protocol-defined dose.
Corticosteroid
Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
JA-Aichi Anjo Kosei Hospital, Anjo-Shi
Nagoya University Hospital, Nagoya
Hokuyukai Sapporo Hokuyu Hospital, Sapporo
Hokkaido University Hospital, Sapporo
Hyogo College of Medicine Hospital, Nishinomiya-Shi
University of Tsukuba Hospital, Tsukuba
Jiaikai Imamura General Hospital, Kagoshima
Tokai University Hospital, Isehara-Shi
Kanagawa Cancer Center, Yokohama
NHO Kumamoto Medical Center, Kumamoto
Tohoku University Hospital, Sendai
Okayama University Hospital, Okayama
Osaka City University Hospital, Osaka
Shizuoka Cancer Center, Nagaizumi-cho
Jichi Medical University Hospital, Shimotsuke-shi
St. Luke's International Hospital, Chūōku
Jikei University Hospital, Minatoku
Lead Sponsor
Incyte Corporation
INDUSTRY